Patrick Daly

DocwireNews

Reduction of hemolysis was significantly correlated with postinfusion transduction efficacy in patients with <a href="https://www.docwirenews.com/page/sickle-cell-disease">sickle cell disease</a> (SCD) treated with lovotibeglogene autotemcel (lovo-cel) from the HGB-206 and HGB-210 clinical trials, according to a presented at the 2024 Tandem Transplant &amp; Cellular Therapy Meetings of ASTCT® and CIBMTR®.
Transduction efficiency, evaluated via peripheral blood (PB) vector copy number (VCN), “is an important predictor of biologic efficacy and correlates with lovo-cel [drug product] attributes,” stated presenting author, Melissa Kinney, PhD, and fellow researchers at bluebird bio, Inc., in Somerville, Massachusetts.
<h2>Preinfusion Lovo-Cel Vector Copy Number Predicts Postinfusion Outcomes</h2>
The <a href="https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/22751" target="_blank" rel="noopener">analysis</a> included 47 patients with SCD from HGB-210 or group C of HGB-206 who received a single infusion of lovo-cel by February 13, 2023. A multivariate analysis was used to identify associations between transduction efficacy measures and hematological or hemolytic measures, and then a cross-validated random forest regression model based on 15 drug product attributes was used to identify factors that predicted PB VCN.
The analysis found an inverse correlation between PB VCN and hemoglobin (Hb)AT87Q levels and reticulocyte count, bilirubin levels, and erythropoietin — measures of transduction efficiency and hemolysis, respectively.
“This indicates that a higher proportion of transduced cells is associated with an increased resolution of sickle cell–associated hemolysis,” wrote Dr. Kinney and colleagues.
An assay that evaluates the propensity of sickling in red blood cells also showed a significant correlation with total hemoglobin after lovo-cel treatment. The authors expanded the regression model and further found that lovo-cel VCN in the myeloid lineage was the greatest preinfusion factor for predicting PB VCN.
Overall, “attributes of DP transduction efficiency as well as the resulting PB VCN predict successful treatment outcomes with lovo-cel,” concluded the study’s authors.
Related: <a href="https://www.docwirenews.com/post/what-are-the-factors-that-influence-response-to-canakinumab-therapy">What Are the Factors That Influence Response to Canakinumab Therapy?</a>
&nbsp;
Reference
Kinney MA, Shestopalov I, Christiansen L, et al. Abstract #302. Predictors of biologic efficacy with lovotibeglogene autotemcel (lovo-cel) gene therapy in patients with sickle cell disease. Presented at the 2024 Tandem Transplant &amp; Cellular Therapy Meetings of ASTCT® and CIBMTR®. February 21-24, 2024; San Antonio, Texas.

Emily Menendez

Non-Invasive NETseq Classifier Determines NET Diagnosis With High Accuracy, Sensitivity

GEP-NETs

High Tumor Mutational Burden Linked to Worse OS, RFS in Patients with HCC

Hepatocellular Carcinoma

Cecilia Brown

IASLC and LCRF Award Team Science Grant for Work on Immune-Based Approaches to Target Drug-Resistant Lung Cancer Cells

Lung Cancer

Latest News

Analysis Finds Preinfusion Factors that Predict Lovo-Cel Efficacy in SCD

Sickle Cell Disease

Reduction of hemolysis significantly predicted postinfusion transduction efficacy in patients with SCD treated with lovo-cel.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe